Written and maintained by CASRAI Editorial Board
Last updated
Non-clinical documentation notice: This reference describes validated geriatric frailty rating instruments, epidemiological cohort validations, and clinical trial eligibility stratification methodology for health services and clinical researchers. It does not provide individualized patient prognosis or clinical treatment advice.
The Rockwood Clinical Frailty Scale (CFS, currently in Version 2.0) is a judgment-based, 9-point ordinal rating instrument developed by Kenneth Rockwood and colleagues at Dalhousie University to summarize the overall fitness or frailty level of an older adult after a comprehensive clinical evaluation. Originally validated in the Canadian Study of Health and Aging (CSHA, Rockwood et al., CMAJ 2005;173(5):489–495, read 2026-11-10 at https://www.cmaj.ca/content/173/5/489) and updated to the 9-level CFS Version 2.0 in 2020 (Rockwood & Theou, Can Geriatr J 2020;23(3):210–215, read 2026-11-10 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458601/), the scale integrates comorbidity burden, cognitive status, mobility, instrumental activities of daily living (IADLs), and basic activities of daily living (evaluated via instruments such as the Katz Index of ADL). Together with our companion overview of the Clinical Frailty Scale, this guide details the CFS 2.0 9-point criteria, contrasts Rockwood’s deficit accumulation model with the Fried Frailty Phenotype and Edmonton Frail Scale, and outlines clinical trial stratification governance.
How is the 9-point Rockwood Clinical Frailty Scale (CFS 2.0) scored from 1 (Very Fit) to 9 (Terminally Ill)?
Originally published in 2005 as a 7-point scale, the Rockwood CFS was expanded in 2007 and refined in the 2020 CFS Version 2.0 revision into 9 distinct categories to differentiate severe frailty, very severe frailty, and terminal illness. A foundational rule of CFS 2.0 administration in acute hospital or emergency settings is the 2-week baseline rule: clinicians and research coordinators must score the patient based on their baseline functional capability 2 weeks prior to the acute illness or hospitalization, rather than their transient functional impairment on the day of acute presentation.
| CFS 2.0 Level | CFS 2.0 Category Title (2020 Revision) | Core Functional, IADL, and BADL Defining Criteria |
|---|---|---|
| 1 | Very Fit | Robust, active, energetic, and motivated; exercises regularly and is among the fittest for their age. |
| 2 | Fit | No active disease symptoms, but less fit than Category 1; exercises or is very active occasionally (e.g., seasonally). |
| 3 | Managing Well | Medical problems are well controlled, even if occasionally symptomatic; not regularly active beyond routine walking. |
| 4 | Living with Very Mild Frailty (Formerly “Vulnerable” in CFS 1.2) |
Not dependent on others for daily help, but symptoms often limit activities; common complaints of being “slowed up” and/or tired during the day. |
| 5 | Living with Mild Frailty | More evident slowing; requires help with high-order IADLs (finances, transportation, heavy housework, medications). Typically progressively impairs shopping, walking outside alone, meal preparation, and housework. |
| 6 | Living with Moderate Frailty | Requires help with all outside activities and with keeping house; indoors, often has problems with stairs, needs help with bathing, and might need minimal assistance (cuing, standby) with dressing. |
| 7 | Living with Severe Frailty | Completely dependent for personal care (BADLs) from whatever cause (physical or cognitive). Even so, appears stable and not at high risk of dying within the next 6 months. |
| 8 | Living with Very Severe Frailty | Completely dependent for personal care and approaching the end of life; typically could not recover even from a minor illness. |
| 9 | Terminally Ill | Approaching the end of life with a life expectancy of < 6 months, who are not otherwise living with severe frailty (many terminally ill patients can still exercise until very close to death; if severely frail at baseline, score as Category 7 or 8). |
Scoring Dementia on the Rockwood CFS 2.0
Per Rockwood & Theou (2020), when frailty is driven primarily by cognitive impairment, the degree of dementia corresponds directly to the degree of frailty:
- Mild dementia (`CFS 5`): Forgets the details of a recent event, though still remembering the event itself; repeats the same question/story and shows social withdrawal (loses IADL independence).
- Moderate dementia (`CFS 6`): Recent memory is very impaired, even though they seemingly can remember their past life events well; can do personal care with prompting or standby assistance.
- Severe dementia (`CFS 7`): Cannot do personal care without help across basic activities of daily living.
How does the Rockwood Deficit Accumulation Frailty Index differ from the 5-item Fried Frailty Phenotype and Edmonton Frail Scale?
In geriatric epidemiology and clinical trial design, frailty is operationalized through two competing conceptual paradigms that identify overlapping but non-identical patient cohorts:
- The Cumulative Deficit Accumulation Model (Rockwood & Mitnitski): Conceptualizes frailty as an age-related state of multidimensional vulnerability arising from the accumulation of health deficits across symptoms, signs, diseases, disabilities, and laboratory abnormalities. The quantitative Rockwood Frailty Index (`FI`) is calculated as the ratio of deficits present in an individual divided by the total number of deficits measured (requiring at least 30–70 variables; e.g.,
15 deficits present / 50 evaluated = FI of 0.30). In the CSHA validation cohort (`n = 2,305`), the 1-to-9 judgment-based Clinical Frailty Scale (CFS) correlated strongly with the mathematical Frailty Index (Pearsonr = 0.80,p < 0.01), and each 1-category increment on the CFS independently increased 5-year mortality (hazard ratio1.30, 95% CI1.27–1.33) and institutionalization (hazard ratio1.46, 95% CI1.39–1.53). - The Biological / Physical Phenotype Model (Fried et al., Cardiovascular Health Study, J Gerontol A Biol Sci Med Sci 2001;56(3):M146–M156, read 2026-11-10 at
https://academic.oup.com/biomedgerontology/article/56/3/M146/545770): Conceptualizes frailty as a distinct clinical syndrome driven by sarcopenia and neuroendocrine/energy dysregulation, distinct from disability and comorbidity.
| Instrument | Conceptual Framework & Developer | Measured Domains & Equipment Required | Scoring Range & Frailty Cutoffs |
|---|---|---|---|
| Rockwood Clinical Frailty Scale (CFS 2.0) | Deficit accumulation clinical synthesis (Rockwood et al., 2005 / 2020) | Clinical history of physical activity, disease symptom control, IADLs, BADLs, and cognition (2 weeks prior to acute illness); no specialized equipment required. | 1 to 9 ordinal scale:1–3 Non-frail (Fit/Managing well)4 Very mild frailty5–8 Mild to very severe frailty9 Terminally ill |
| Rockwood Frailty Index (FI-30 to FI-70) | Mathematical deficit accumulation ratio (Mitnitski & Rockwood, 2001) | 30 to 70 binary/ordinal health deficits (comorbidities, symptoms, labs, functional impairments); computable as an Electronic Frailty Index (eFI) from EHR data. | 0.00 to 1.00 continuous ratio (submaximal empirical limit ~0.65–0.70); frailty commonly defined at FI >= 0.25. |
| Fried Frailty Phenotype (CHS Index) | Physical/biological syndrome phenotype (Fried et al., 2001) | 5 physical criteria: (1) unintentional weight loss (>=10 lb/year), (2) self-reported exhaustion (CES-D items), (3) low physical activity (kcal/week), (4) slow 15-ft gait speed, and (5) weak grip strength (handheld dynamometer). | 0 to 5 points:0 Robust1–2 Pre-frail>= 3 Frail |
| Edmonton Frail Scale (EFS) | Multidimensional performance + questionnaire screen (Rolfson et al., Age Ageing 2006;35(5):526–529) | 9 domains: cognition (Clock Drawing Test), general health status, functional independence (IADLs), social support, polypharmacy, nutrition, mood, continence, and mobility (Timed Up and Go). | 0 to 17 points:0–5 Not frail6–7 Vulnerable8–9 Mild frailty10–11 Moderate frailty12–17 Severe frailty |
How is frailty assessment used for geriatric risk stratification and clinical trial eligibility?
In oncology, structural heart intervention (such as transcatheter aortic valve replacement), peri-operative risk stratification (alongside instruments like the STOP-BANG score), and phase II/III clinical trials, chronological age alone poorly predicts treatment toxicity, post-operative delirium, or non-cancer competing mortality. Integrating the Rockwood CFS 2.0 into clinical trial protocols serves three methodological functions:
- Eligibility and Subgroup Stratification: Rather than imposing arbitrary upper chronological age cutoffs (e.g., excluding patients aged >75 years), modern geriatric oncology and cardiology trials stratify randomization by baseline CFS score (commonly grouping
CFS 1–3fit/robust,CFS 4–5very mild-to-mild frailty, andCFS 6+moderate-to-severe frailty) alongside patient-reported functional domains such as PROMIS-29. - Classification Tree Standardization and Inter-Rater Reliability: To reduce inter-rater variability among research coordinators, Dalhousie University published a validated CFS Classification Tree (Theou et al., Age Ageing 2021) that walks assessors step-by-step through terminal illness (`CFS 9`), BADL dependency (`CFS 6–8`), IADL dependency (`CFS 5`), symptom limitation (`CFS 4`), and regular exercise (`CFS 1–3`). When evaluating prediction models that incorporate CFS scores across external hospitals, investigators should verify calibration and discrimination using internal vs external validation standards.
- Copyright and Research Licensing Governance: The Clinical Frailty Scale is copyrighted by Kenneth Rockwood and associates at Dalhousie University. Non-commercial clinical care, public health, research, and educational users can obtain a royalty-free permission license directly through Dalhousie University Office of Commercialization and Industry Engagement, whereas commercial clinical trial sponsors and EHR software vendors require a commercial license agreement.
Frequently Asked Questions
How is the 9-point Rockwood Clinical Frailty Scale (CFS 2.0) scored from 1 (Very Fit) to 9 (Terminally Ill)?
CFS Version 2.0 rates baseline function 2 weeks prior to acute illness from 1 (Very Fit), 2 (Fit), and 3 (Managing Well) to 4 (Living with Very Mild Frailty, slowed up/tired), 5 (Mild Frailty, requires help with high-order IADLs), 6 (Moderate Frailty, needs help with all outside activities and bathing/minimal dressing), 7 (Severe Frailty, completely dependent for personal care), 8 (Very Severe Frailty, approaching end of life), and 9 (Terminally Ill, life expectancy <6 months without otherwise severe frailty).
How does the Rockwood Deficit Accumulation Frailty Index differ from the 5-item Fried Frailty Phenotype and Edmonton Frail Scale?
The Rockwood Frailty Index (`FI`) and Clinical Frailty Scale (`CFS`) measure cumulative multidimensional health deficits (including cognition, comorbidities, IADLs, and BADLs), whereas the 5-item Fried Frailty Phenotype assesses a physical syndrome (weight loss, exhaustion, low activity, slow gait speed, and weak grip strength) and the 17-point Edmonton Frail Scale (`EFS`) combines a Clock Drawing Test, Timed Up and Go, and 7 questionnaire domains.
How is frailty assessment used for geriatric risk stratification and clinical trial eligibility?
Clinical trials use the Rockwood CFS 2.0 to replace chronological age exclusions with functional stratification (`CFS 1–3` vs. `4–5` vs. `6+`), adjust chemotherapy or surgical intensity, and model competing mortality risks, using the Dalhousie CFS Classification Tree to standardize scoring across multicenter trial sites.
